Medical record review of transition to lanreotide following octreotide for neuroendocrine tumors | Zendy

Muhammad Wasif Saif | Zendy; Rohan Parikh | Zendy; David Ray | Zendy; James A. Kaye | Zendy; Samantha K. Kurosky | Zendy; Katharine Thomas | Zendy; Robert A. Ramirez | Zendy; Þorvarður R. Hálfdánarson | Zendy; Thomas J.R. Beveridge | Zendy; Beloo Mirakhur | Zendy; Saurabh Nagar | Zendy; Heloisa P. Soares | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Medical record review of transition to lanreotide following octreotide for neuroendocrine tumors

Author(s) -

Muhammad Wasif Saif,

Rohan Parikh,

David Ray,

James A. Kaye,

Samantha K. Kurosky,

Katharine Thomas,

Robert A. Ramirez,

Þorvarður R. Hálfdánarson,

Thomas J.R. Beveridge,

Beloo Mirakhur,

Saurabh Nagar,

Heloisa P. Soares

Publication year - 2019

Publication title -

journal of gastrointestinal oncology

Language(s) - English

Resource type - Journals

eISSN - 2219-679X

pISSN - 2078-6891

DOI - 10.21037/jgo.2019.03.11

Subject(s) - lanreotide , medicine , octreotide , neuroendocrine tumors , progressive disease , progression free survival , gastroenterology , surgery , somatostatin , disease , chemotherapy , acromegaly , growth hormone , hormone

Octreotide has been used for decades in the United States (US) and Europe to treat patients with advanced neuroendocrine tumors (NETs). Lanreotide was approved in 2014 to improve progression-free survival (PFS) in patients with unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic NETs. Therefore, clinicians and patients may consider sequencing therapy from octreotide to lanreotide. However, current real-world outcomes data on patients who have made this transition is limited.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research